Figure 8. MyBP‐C phospho‐ablation disrupts in vivo systolic pressure development after β‐adrenergic stimulation .

A, β‐adrenergic stimulation by dobutamine administration decreases maximum systolic pressure development to accommodate an increased HR (see WT and TnI^PKA−). MyBP‐C phospho‐ablation, however, results in significantly reduced systolic blood pressure after β‐adrenergic stimulation because of an inability to fully accelerate pressure development in the absence of MyBP‐C phosphorylation. SBP, systolic blood pressure. B, time to peak systolic blood pressure was significantly decreased by dobutamine administration in WT and TnI^PKA− mice but was not significantly shortened from baseline in MyBPC^PKA‐ and DBL^PKA− mice and was significantly longer (after dobutamine) compared to WT. *Significantly different from the corresponding baseline group (without dobutamine treatment) (P < 0.05). ^†Significantly different from WT under the same treatment (i.e. post‐dobutamine) (P < 0.05).